Fig. 3

Presence of circulating Th22 and Tc22 cells in CVID patients. PBMCs from healthy controls (HC, n = 16) and CVID patients (n = 16) were cultivated with medium (baseline) or agonists of TLR3 (Poly-RIG) and TLR7/8 (CL097) for 20 h or SEB for 6 h and assessed by flow cytometry. a Th22 and b Tc22 cell frequencies were obtained by excluding IFN-γ and IL-17a. Data represent the median and the interquartile range. *p ≤ 0.05, **p ≤ 0.01